Sharing Addiction Treatment Outcomes Data Honestly

A single percentage on a treatment center website draws three follow-up questions from payers and families: success at what, measured how, and out of whom. Centers that publish addiction treatment outcomes data with a clear definition win that conversation, while centers that publish a bare percentage lose it. That pressure lands directly on your website, your ads and your payer packets.

The public evidence on addiction as a condition, the outcome measures you can publish honestly, the methods note and the claims that create FTC or ad-platform risk all follow below, written for CEOs, clinical directors and admissions leaders.

Addiction Treatment Outcomes Data at a Glance

There's no single national success rate for addiction treatment, and any program that quotes one is choosing a definition for you. Outcomes depend on the substance, the level of care, baseline severity, how long patients stay and what's counted as success (source). Abstinence at 12 months, reduced use, retention in care, fewer overdoses and better function are all legitimate outcomes, and they produce very different numbers from the same patients.

Your published figure is only as defensible as the definition beside it. The sections below start with the clinical context payers already understand, then move to how you report your own results.

Addiction as a Chronic Condition

The National Institute on Drug Abuse describes addiction as a chronic condition that treatment manages rather than cures. It compares relapse rates of 40% to 60% to those of other chronic illnesses such as hypertension and asthma (source). Judging a chronic condition by a single discharge-day snapshot will overstate or understate what the program did.

Prevalence, Risks and Co-Occurring Disorders

A widely used public source for prevalence is the National Survey on Drug Use and Health, run by SAMHSA. It reports how many people meet criteria for a substance use disorder, how many receive treatment and how often mental health conditions overlap (SAMHSA data). Cite it by name and year when you use population figures, and never present a national number as your own result.

Co-occurring disorders change how you read any outcome. A program serving patients with untreated depression, trauma or bipolar disorder faces a different baseline than one serving a lower-acuity population. Dual diagnosis programs also need clinical nuance in how they describe results, because abstinence alone can miss improvement in mood or function.

Addiction Treatment Success Rates and Recovery Statistics

Relapse Rates and What They Really Mean

You can't compare a relapse rate across programs unless the definition travels with it. In one review of 22 studies, nine counted zero reported consumption as no relapse and 13 used something else (PMC review). So say whether one lapse counts or only a return to prior patterns of use, and whether the window starts at admission or at discharge. Also say whether a patient who returns to treatment is counted as a failure or as engagement.

Pick the definition your clinical team already uses in the chart, publish it, and keep it stable year to year. Don't minimize relapse and don't imply the program prevents it. Relapse is common in a chronic condition (NIDA figures), and the plan for it, including re-engagement and step-up in care, is part of the service.

Outcomes by Substance and Treatment Type

Alcohol use disorder, opioid use disorder and stimulant use disorder follow different courses and respond to different treatments, and blending them into one headline figure hides that. The same logic applies to levels of care. The federal DATOS study, for example, covered 96 programs in 11 U.S. cities and examined program type, client characteristics, length of services and aftercare (ICPSR).

Detox in particular is a stabilization step for withdrawal symptoms, not a treatment outcome in itself. Reporting detox completion next to 12-month abstinence rates as if they measure the same thing misleads readers. Report each level of care separately and describe who you served at each one.

What Makes Addiction Treatment Effective in the Published Evidence

Evidence-Based Behavioral Therapies and Medications

Cognitive behavioral therapy, motivational interviewing and contingency management have published support for substance use disorder, and the National Institute on Drug Abuse summarizes the principles of effective care. The CDC says medications for opioid use disorder, including buprenorphine and methadone, help people reduce illegal opioid use, stay in treatment longer and lower overdose risk (CDC).

Cite those studies as external evidence for the approach. Don't attribute the effect to your program, because a study finding about buprenorphine isn't a result your patients achieved.

A Full Continuum of Care

Retention and service intensity are legitimate process measures you can publish alongside outcomes. Examples include the share of patients who step down to a lower level of care, median length of stay by level, and the share who attend aftercare appointments. The literature associates retention with reduced drug use and better quality of life (PMC review), so frame these as associations, not guarantees.

How to Read and Report Outcomes Data Critically, in Four Steps

Start with the denominator. A rate calculated from patients who completed treatment will be higher than one calculated from everyone admitted, because completers are a self-selected group. Publish completion and sustained abstinence as two separate figures, each with its own denominator (definitions vary by study), and say which patients are in each.

Then address patients lost to follow-up. Published follow-up windows range from 30 days to 9 years after discharge, with 1-month and 6-month periods most common (PMC review). If a center can't reach a large share of a cohort, it can't assume those patients did well. State your follow-up rate beside the result and report the unreachable group explicitly.

Name the data source. Self-report is the most common method and a recognized limitation, since patients may under-report use. In the same review, nine abstinence studies and 11 relapse papers used urine, breath or blood samples (PMC review). Your methods note should say which verification you used and for what share of patients.

Describe case mix too, including who you served by primary substance, co-occurring conditions, prior treatment episodes and baseline severity (DATOS variables). Fair comparison between centers requires risk adjustment, and when you can't do that, describing the population is the minimum.

What Breaks FTC and Ad-Platform Rules

The FTC requires that health claims be truthful and substantiated before you make them. Under its health products compliance guidance, the level of proof expected depends on what the claim says, and a claim of effectiveness generally needs competent and reliable scientific evidence. Success-rate claims therefore need a clear method, a defined sample and a stated time frame.

Several patterns create risk. A headline rate with no definition, a rate drawn only from completers and presented as all patients, a comparison to competitors you can't substantiate, and words like proven or guaranteed without the studies behind them all invite scrutiny. Evidence-based should refer to named, published practices you actually deliver, with fidelity you can document.

Advertising adds a second layer. Google and Meta both restrict addiction treatment advertising, and Google's addiction services policy requires LegitScript certification before treatment providers can advertise. Policies change, so confirm current rules directly with each platform before you put outcome statistics in ad copy. Landing pages should carry the full methods note even when the ad itself can't.

Privacy sets the last boundary. Published outcomes should be aggregated and de-identified, and patient stories need written consent that meets HIPAA and 42 CFR Part 2 requirements. Have counsel review how small cell sizes could identify a person before anything goes live.

How Sweet Media Supports Outcomes Reporting

Sweet Media is a behavioral health digital marketing agency in Costa Mesa, California, and we treat outcomes pages as admissions infrastructure rather than decoration. That means working from your clinical team's definitions, drafting the methods note in plain language and building service pages that match what people search for at each level of care.

Where we cite results from our own work, we publish them with their context. In the Rize OC case study, cost per acquisition fell 67 percent, from $350 to $115, as monthly ad spend scaled to $300K. That's a marketing result for a named client, not a clinical outcome, and we keep that line clear in how we write.

Our SEO work covers the page structure, schema and trust signals that let outcome content rank without overstating anything. Our paid media work follows the same rules, including the ad-policy constraints above.

An Eight-Point Checklist for Evaluating Outcome Claims Before Publishing

Run every outcome statement through these eight checks before it goes on a page, into an ad or into a payer packet. Each one maps to a point covered above, starting with the denominator and ending with de-identification.

1. 1Name the exact outcome definition, look-back window, and 30-day or 12-month follow-up point.
2. 2State the full denominator clearly and separate program completers from all admissions.
3. 3Disclose the cohort follow-up response rate and account for unreachable alumni explicitly.
4. 4Name the measurement instrument, who collected the data, and whether results were self-reported or lab-verified.
5. 5Break out outcomes by level of care and describe clinical acuity and population context.
6. 6Limit national benchmark comparisons to matching definitions and label them clearly as external context.
7. 7Remove words like proven, guaranteed, or cure unless peer-reviewed clinical substantiation is on file.
8. 8Obtain written legal sign-off confirming HIPAA and 42 CFR Part 2 de-identification and consent.

Frequently Asked Questions

What is the success rate of substance abuse treatment?

There's no single rate, because success depends on the definition, the substance, the level of care and the follow-up period (source). Public sources such as NIDA and SAMHSA describe substance use disorder as chronic and relapsing, so ask which outcome is being measured before accepting any figure.

What FTC substantiation is needed for claims like proven or evidence-based?

The FTC expects health claims to be truthful and backed by evidence before they run. A claim that a program is evidence-based should point to specific published practices you deliver, and a claim of proven results needs your own method, sample and time frame documented.

Does Google Ads allow outcome statistics for addiction treatment?

Google restricts addiction treatment advertising and requires LegitScript certification, and policies on claims change. Check current Google and Meta policies before using statistics in ad copy, and send traffic to a page that carries the full methods disclosure.

How should we handle patients lost to follow-up?

Report the follow-up rate beside the result and don't assume unreachable patients did well (follow-up windows vary widely). Show the outcome for the patients you reached and state clearly how many you couldn't contact.

Can we publish outcomes and stay within HIPAA and 42 CFR Part 2?

Yes, if the data is aggregated and de-identified, small cell sizes are checked for re-identification risk, and any patient story has compliant written consent. Have counsel review the final page.

If you want your outcomes content reviewed against these standards, you can book a free strategy call or request a free media audit, and we'll show you where current claims carry risk and where honest proof can carry more weight.